Test Price
2,800 AED✅ Home Collection Available
TYR Gene (Oculocutaneous Albinism Type 1B) Genetic Test in UAE | 2800 AED | DHA Approved
Executive Summary & Core Metrics
Definitive Diagnosis for OCA1B via Next‑Generation Sequencing
This targeted NGS assay analyses all coding exons and flanking intronic regions of the TYR gene – the definitive molecular cause of oculocutaneous albinism type 1B (OCA1B). With a diagnostic sensitivity exceeding 99.9% and ISO‑certified cold‑chain processing, the test differentiates OCA1B from other hypopigmentation disorders. Results are delivered in 3–4 weeks, guiding dermatologic, ophthalmologic, and genetic counselling decisions. All sample collection is performed by VIP mobile phlebotomy (8 AM – 11 PM) or via direct drop‑off at our accredited facility.
✅ Diagnostic Accuracy
>99.9% sensitivity for SNVs and small indels
🚚 VIP Home Collection
Mobile phlebotomy daily 8 AM – 11 PM; temperature‑controlled cold‑chain transport
📋 Mandatory Pre‑Test Counselling
Genetic counselling session included; informed consent per UAE Law
💰 Insurance & Direct Billing
Send card via WhatsApp +971 54 548 8731; coverage verified within 1 working day
Test Overview & Methodology
This targeted Next‑Generation Sequencing (NGS) assay analyses all coding exons and flanking intronic regions of the TYR gene – the definitive molecular cause of oculocutaneous albinism type 1B (OCA1B). The test differentiates OCA1B from other hypopigmentation disorders with a single blood or FTA card sample, delivering results in 3–4 weeks to guide dermatologic, ophthalmologic, and genetic counselling decisions.
| Parameter | Our Test (NGS) | Conventional Sanger Sequencing |
|---|---|---|
| Gene Coverage | Full TYR coding region + 20 bp intronic flanks | Single exon or limited amplicon; may miss deep intronic mutations |
| Sensitivity | >99.9% for single‑nucleotide variants & small indels | ~95% when targeting known hotspots; lower for novel variants |
| Turnaround | 3–4 weeks | Often 6–8 weeks if batched |
| Clinical Utility | Definitive subtyping (OCA1A vs 1B), family planning, prenatal options | Limited confirmatory role; rarely clarifies genotype‑phenotype correlation |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I must emphasise that a TYR mutation report is a guide, not a verdict. Albinism is a spectrum – OCA1B often retains some pigmentation, and visual impairment varies. Always correlate molecular findings with a thorough dermatology and ophthalmology exam, and never discontinue any prescribed treatment or sun protection solely based on this test. We are committed to supporting your patient journey with safe, precise, and compassionate care.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory: Medication & Treatment Continuation
⚠️ Do not discontinue prescribed medication without consulting your doctor. This test is a molecular diagnostic aid; it does not replace clinical judgment or ongoing therapy.
Exclusion Criteria & Emergency Red Flags
- Home phlebotomy is contraindicated if the patient has a bleeding disorder or is on therapeutic anticoagulation without medical clearance.
- Minors must be accompanied by a legal guardian; per Federal Decree-Law No. 4 of 2016 on Medical Liability, testing a child requires explicit, documented informed consent.
- Red Flags: Seek immediate medical attention if you develop sudden vision loss, suspicious skin lesions, or signs of melanoma (changing mole, bleeding) – these are unrelated to OCA1B but demand urgent evaluation.
Patient FAQ & Clinical Guidance
1. What exactly does the TYR gene NGS test detect and why is it needed?
This NGS test detects mutations in the TYR gene to confirm Type 1B oculocutaneous albinism diagnosis with 99.9% accuracy. It sequences all coding exons and nearby splice sites, identifying pathogenic variants that reduce tyrosinase activity. This helps dermatologists and genetic counsellors differentiate OCA1B from other albinism types, predict visual prognosis, and guide sun protection and family planning.
2. How should I prepare for the sample collection and what pre-test steps are mandatory?
All patients must attend a mandatory genetic counselling session to draw a detailed pedigree chart of family members affected by TYR-related albinism. A clinical history form must be submitted prior to collection; no fasting is required. Blood, extracted DNA, or a single drop on an FTA card can be used. The session ensures informed consent and accurate clinical correlation, aligning with UAE medical privacy laws and DHA standards.
3. Will insurance cover this test and how do I initiate the process?
Many UAE insurers cover genetic testing when medically indicated and pre-authorized. Send your insurance card photo via WhatsApp to +971 54 548 8731; our billing team will verify coverage within one working day. If covered, we handle direct billing. For self-pay, the cost is 2800 AED, inclusive of home collection, genetic counselling, and post-test clinical guidance.
4. What is the turnaround time and how will I receive results?
Results are typically available in 3–4 weeks from sample arrival at the laboratory. A comprehensive molecular report including variant interpretation and clinical recommendations will be sent via secure email. A follow-up tele-counselling session with our genetics team is scheduled to discuss findings and next steps.
5. Can this test be performed on children?
Yes, pediatric testing is available. However, a legal guardian must provide explicit informed consent during the mandatory pre-test counselling session. The sample collection is minimally invasive (blood or buccal swab) and can be performed at home with prior clearance.
UAE Regulatory & Data Privacy Adherence
Strict Compliance with UAE Laws
This service operates under the regulatory oversight of the Dubai Health Authority (DHA) and complies fully with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – safeguarding your medical and genetic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensuring secure digital health records.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – governing informed consent and clinical accountability.
All molecular testing follows ISO 9001:2015 certified workflows (Cert: INT/EGQ/2509DA/3139) under DHA facility license 1143. Home collection is executed by licensed phlebotomists using cold-chain logistics validated per WHO/ICH guidelines.
Clinical & Logistical Metadata
| Test Name | TYR Gene Full Sequencing (OCA1B) – Next‑Generation Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or FTA card – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection Available (8 AM – 11 PM) |
| Methodology Used | Targeted Next‑Generation Sequencing (NGS) – Illumina platform, whole TYR coding region plus 20 bp intronic flanks |
| ICD-10-CM Code | E70.319 (Oculocutaneous albinism, unspecified) |
| LOINC Code | 64652-5 (TYR gene full gene sequencing) |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | DNA Labs UAE – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians